Skip to content
Screener

Pulse Biosciences, Inc. PLSE EBITDA margin

EBITDA margin at other companies

Abbott logo
AbbottABT
23.2%-1.6pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
34.4%+2.5pp
Boston Scientific logo
Boston ScientificBSX
25.2%+1.6pp
AtriCure logo
AtriCureATRC
-1.2%-0.5pp
Medtronic logo
MedtronicMDT
25.9%-0.4pp
Merit Medical Systems logo
Merit Medical SystemsMMSI
20.2%+0.9pp

Other financials

Income statement

See full
Revenue$434.0K—
Gross profit$161.0K—
Operating income-$25.3M-24.6%
Net income-$24.7M-28.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$101.6M-4.4%
Total debt$6.8M-17.9%
Total equity$99.5M-4.8%
Total assets$115.6M-3.9%

Cash flow

See full
Operating cash flow-$18.7M-46.1%
CapEx$90.0K-12.6%
Free cash flow-$18.8M-45.6%

Valuation

See full
Market cap$2.96B+196%
Enterprise value$2.87B+217%
P/S2,498.4×—

Profitability

See full
Gross margin-0.1%—
Operating margin-7,007.8%—
Net margin-6,755.8%—
FCF margin-5,180.4%—

Returns & leverage

See full
Return on equity-78.5%-15.3pp
Debt / equity0.1×0.0×
Current ratio9.6×-2.4×

Where this comes from

Calculated from Pulse Biosciences, Inc.’s reported figures.

ebitda/total revenue=-6,920.5%

Based on trailing twelve months.

The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437749-26-026288

FAQ

What is Pulse Biosciences, Inc.'s EBITDA margin?
Pulse Biosciences, Inc. (PLSE) reported EBITDA margin of -6,920.5% in Q2 2026.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Ask your AI about Pulse Biosciences, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude